Gabapentin
- Generic Name
- Gabapentin
- Brand Names
- Gralise, Neurontin
- Drug Type
- Small Molecule
- Chemical Formula
- C9H17NO2
- CAS Number
- 60142-96-3
- Unique Ingredient Identifier
- 6CW7F3G59X
- Background
Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages ...
- Indication
In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or...
- Associated Conditions
- Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia
- Associated Therapies
- -
Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2008-12-02
- Lead Sponsor
- Usak State Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT00800527
- Locations
- 🇹🇷
Usak State Hospital, Usak, Turkey
Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Walter Reed Army Medical Center
- Target Recruit Count
- 106
- Registration Number
- NCT00793910
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2021-02-03
- Target Recruit Count
- 1
- Registration Number
- NCT00785772
- Locations
- 🇯🇵
Pfizer Investigational Site, Saijyo-shi, Ehime, Japan
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia
- Conditions
- Interventions
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 378
- Registration Number
- NCT00755508
Post-Operative Pain Scores and Analgesic Requirements After Elective Inguinal Herniorrhaphy
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 5
- Registration Number
- NCT00735124
- Locations
- 🇺🇸
OUHSC, Oklahoma City, Oklahoma, United States
Perioperative Use of Gabapentin To Decrease Narcotic Requirements in Spinal Fusion
- Conditions
- Interventions
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 63
- Registration Number
- NCT00726999
Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.
- Conditions
- Interventions
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Women and Infants Hospital of Rhode Island
- Target Recruit Count
- 27
- Registration Number
- NCT00711529
- Locations
- 🇺🇸
Breast Health Center, Program in Women's Oncology, Women & Infants' Hospital of Rhode Island, Providence, Rhode Island, United States
Analgesic Effects of Gabapentin After Scoliosis Surgery in Children
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 35
- Registration Number
- NCT00684112
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 377
- Registration Number
- NCT00674752
- Locations
- 🇺🇸
Pfizer Investigational Site, Cincinnati, Ohio, United States
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 85
- Registration Number
- NCT00667121
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.